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INTRODUCTION
Cervical cancer is the second most common cancer and sec-
ond leading cause of cancer-related deaths in women world-
wide and is highly associated with persistent high-risk types of 
human papillomavirus (HPV) infection.1 HPV 16 and HPV 18 
are related to about 70% of invasive cervical cancer cases, and 
are also associated with other anogenital and oropharyngeal 
cancers.2,3 The incidence of oropharyngeal cancer is increasing 
rapidly, and it has been predicted that the incidence of HPV-in-
duced oropharyngeal cancer will outstrip that of HPV-induced 
cervical cancer.4
Recently, two valid prophylactic vaccines for HPV have been 
shown to effectively prevent the incidence of HPV-associated 
anogenital disease in young women.5 However, only about 30% 
of teenagers qualified for immunization have been inoculated 
with the recommended dose of the vaccine;6 hence, most teen-
agers are not protected from HPV 16- and HPV 18-associated 
cancers. In addition, these prophylactic vaccines do not have a 
therapeutic effect on pre-existing high-risk types of HPV-infect-
ed cervical diseases.7 In spite of conventional treatments, such 
as radiotherapy and chemotherapy, the outcomes of treatments 
for recurrent or advanced-stage HPV-induced cancers are poor.8 
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Therefore, further research on the development of therapeutic 
HPV vaccines is required for HPV-associated cancers.
Previously, several reports have shown that type 1 helper T 
cell-dependent cellular immune responses related to cytotoxic 
T lymphocytes (CTLs) are crucial for the removal of pre-cancer-
ous lesions infected with HPV 16 and HPV 18 as well as HPV-
induced cancers.9,10 HPV 16 E7 is a nuclear protein that sustain 
consistent expression in cervical cancer cells, but not exist in 
normal cells, and have oncogenic properties.1 Thus, they are 
ideal tumor-specific antigen targets for cervical cancer immu-
notherapy, and the identification of CTL epitopes from the E7 
proteins of HPV 16 and HPV 18 is fundamental for the develop-
ment of therapeutic vaccines and immune monitoring systems 
for treated cervical cancer patients.11,12
E7 is known as immunodominant HPV 16 antigens, but only 
a small number of CTL epitopes from E7 have been verified for 
HLA-A*02;01 and HLA-A*24;02 samples.11,13 To establish the 
clinical application of a peptide-based HPV vaccine for cervi-
cal cancer, it is essential to identify immunogenic E7 epitopes 
restricted to each class I HLA-A allele, such as HLA-A*33;03, 
which is common in Asian and African countries; in approxi-
mately 20–30% of the population of Japan, China, Thailand, 
Pakistan, and countries of sub-Saharan Africa.14
The aim of this study was to identify new HLA-A*33;03-re-
stricted epitopes from the HPV 16 E7 protein HLA which can 
be applied as therapeutic vaccines for adoptive immunothera-
py using CD8+ CTLs against cervical cancer.
MATERIALS AND METHODS
Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were collected 
from healthy HLA-A*33;03 donors who were human cytomeg-
alovirus (HCMV) seropositive. The presence of IgG and IgM 
HCMV antibodies in each donor was assessed using passive la-
tex agglutination (CMVSCAN Kit; Becton-Dickinson Microbi-
ology System, Cockeysville, MD, USA). All donors were positive 
for IgG and/or IgM HCMV antibodies. The major histocom-
patibility complex (MHC) class I genotypes were determined 
by sequence-specific polymerase chain reaction using genom-
ic DNA by the HLA laboratory at the Seoul Medical Science 
Institute (Seoul, South Korea). PBMCs were isolated from pe-
ripheral blood of donors by density gradient centrifugation 
using Ficoll-Hypaque 1.077 (Pharmacia Biotech, Wilkstrom, 
Sweden). The isolated mononuclear cells were washed twice 
with phosphate-buffered saline (PBS; Gibco, Grand Island, NY, 
USA) and cryopreserved at -160°C in human AB+ serum con-
taining 10% dimethylsulfoxide (DMSO; Sigma, St. Louis, MO, 
USA). This research was approved by the Institutional Review 
Board of Yonsei University Health System, and all participants 
provided written informed consent.
Synthesis of HPV 16 E7 peptides
A total of fourteen 15-amino acids peptides that overlap by 8 
residues for the HPV 16 E7 protein were synthesized (A & Pep, 
Chungwon-gun, South Korea) (Table 1). After determining the 
candidate immunodominant 15-amino acid peptides through 
screening and the verification test described below, 9- or 
10-amino acid peptides spanning the candidate 15-amino acid 
peptides were synthesized (Table 2). The purity of the synthetic 
peptides was confirmed to be greater than or equal to 95% by 
high-performance liquid chromatography. The peptides were 
diluted in 1% DMSO containing DEPC-treated water (Invitro-
gen, Carlsbad, CA, USA) to working solution concentrations (1 
μg/μL) and stored at -80°C until used.
Table 1. List of 15-Amino Acid Overlapping Peptides Spanning HPV 16 
E7 Protein
No. Amino acid position Amino acid sequence
1 1–15 MHGDTPTLHEYMLL
2 7–21 TLHEYMLDLQPETTD
3 13–27 LDLQPETTDLYCYEQ
4 19–33 TTDLYCYEQLNDSSE
5 25–39 YELNDSSEEEDEID
6 31–45 SSEEEDEIDGPAGQA
7 37–51 EIDGPAGQAEPDRAH
8 43–57 GQAEPDRAHYNIVTF
9 49–63 RAHYNIVTFCCKCDS
10* 55–69 VTFCCKCDSTLRLCV
11 61–75 CDSTLRLCVQSTHVD
12 67–81 LCVQSTHVDIRTLED
13 73–87 HVDIRTLEDLLMGTL
14 79–93 LEDLLMGTLGIVCPI
15 85–99 GTLGIVCPICSQKP
*HPV 16 E755-69 was not synthesized due to low purity (<50%) using the high-
perfomance liquid chromatography method.
Table 2. List of 9- or 10-Amino Acid Overlapping Peptides Spanning E749-63
No. Amino acid position Amino acid sequence
1 49–57 RAHYNIVTF
2 50–58 AHYNIVTFC
3 51–59 HYNIVTFCC
4 52–60 YNIVTFCCK
5 53–61 NIVTFCCKC
6 54–62 IVTFCCKCD
7 55–63 VTFCCKCDS
8 49–58 RAHYNIVTFC
9 50–59 AHYNIVTFCC
10 51–60 HYNIVTFCCK
11 52–61 YNIVTFCCKC
12 53–62 NIVTFCCKCD
13 54–63 IVTFCCKCDS
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Generation of autologous dendritic cells and peptide-
specific CTLs
Peptide-loaded autologous dendritic cells (DCs) were generat-
ed as previously described, with minor modifications.15 PBMCs 
were incubated at 37°C for 2 hours in complete RPMI medium 
(Gibco, Grand Island, NY, USA) containing 10% fetal bovine se-
rum (FBS) (Gibco) and 1% antibiotics (Invitrogen). Adherent 
monocytes were resuspended at a concentration of 5×106 cells/
mL in complete RPMI medium supplemented with granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) (1500 
IU/mL; PeproTech, Rocky Hill, NJ, USA) and interleukin (IL)-4 
(1200 IU/mL; PeproTech). On days 2, 4, and 6 of culture, fresh 
cytokines were added. On day 5 of culture, 10 ng/mL of tumor 
necrosis factor-α (TNF-α) (R&D Systems, Minneapolis, MN, 
USA) was added to induce maturation of DCs. After matura-
tion, autologous DCs were stimulated with peptides for 6 hours. 
PBMCs were plated at a concentration of 2×106 cells per well 
in a 24-well plate (Nunc, Rochester, NY, USA) with 2 mL of 
complete RPMI medium. PBMCs were sensitized with syn-
thetic HPV 16 E7 peptides (10 μg/mL/well), and 1000 IU/mL/
well of recombinant human IL-2 (rhIL-2; PeproTech) was add-
ed. Additionally, rhIL-2 (1000 IU/mL/well) was added to the 
culture every other day. After a 1-week expansion period, pep-
tide-pulsed autologous DCs (4-10×106/well) were added to the 
PBMCs on day 7, incubated for 6 hours, and analyzed by flow 
cytometry. DC-treated PBMCs were cultured for additional 7 
days, and used for cytotoxicity assays. CD8-positive and -neg-
ative cells were isolated from 2-week-sensitized PBMCs for 
the cytotoxicity assay using Dynabeads® FlowCompTM Human 
CD8 Kit (Invitrogen).
Flow cytometry analysis
PerCP-conjugated anti-CD3, PE-conjugated anti-CD8, FITC-
conjugated anti-intracellular interferon-γ (IFN-γ), and PerCP-
conjugated anti-CD69 were purchased from BD Biosciences 
(San Jose, CA, USA). For each sample, 75000 events were ac-
quired in the FSC/SSC lymphocyte gate using a FACSCalibur 
flow cytometer (BD Biosciences). For data analysis using CEL-
LQuest software (BD Biosciences), CD8+IFN-γ+ cells were ex-
pressed as the percentage of the respective reference popula-
tion. The evaluation of responses was previously described in 
detail.16 Briefly, peptide-sensitized PBMCs (1×106 cell/mL) 
stimulated with phytohemagglutinin (PHA; Sigma, St. Louis, 
MO, USA) and PBMCs stimulated with autologous DCs load-
ed with none of the peptides were used for the positive and 
negative control groups, respectively. PBMCs stimulated with 
autologous DCs loaded with CMV pp65495–503 (NLVPM-
VATV, HLA-A*02;01) or CMV pp6591-100 (SVNVHNPTGR, HLA-
A*33;03) were used for the positive or negative control accord-
ing to the HLA type of donors. INF-γ produced in CD3+CD8+ 
CTLs was calculated as previously described.11 After one-hour 
stimulation, 10 μg of brefeldin A (Sigma, St. Louis, MO, USA) 
was added to each well. After an additional 5 hours of incuba-
tion, PBMCs were washed once with PBS and were then incu-
bated in PBS containing 1 mM EDTA for 10 minutes. After two 
washes with PBS containing 5% FBS, the cells were incubated 
with fluorescence-conjugated monoclonal anti-CD3+, anti-
CD8+, anti-INF-γ+, and anti-CD69 antibodies for 15 minutes 
on ice in the dark. 
Enzyme linked immunospot (ELISpot) assay 
IFN-γ production was determined in CD8+ T cell stimulated 
with HPV 16 E7 peptides. After a 1-week expansion period, 
peptide-pulsed autologous DCs (4-10×106/well) were added to 
the PBMCs on day 7, incubated overnight. After incubation, 
CD8+ T cells were isolated from PBMCs using Dynabeads® 
FlowCompTM Human CD8 Kit (Invitrogen). Then, 3×105 cells/
well were plated in triplicate for each treatment in the Enzyme 
linked immunospot (ELISpot) plates (Millipore, Billerica, MA, 
USA). Plates were previously coated with anti-IFN-γ antibody 
(Mabtech, Nacka Strand, Sweden) at 4°C overnight. CD8+ T 
cells were incubated with HPV 16 E7 peptides at 37°C and 5% 
CO2. PHA was added at 10 μg/mL as a positive control, with 
RPMI only as a negative control. After 24 hours incubation, 100 
μL of Biotinylated IFN-γ detection antibody diluted in 1:2000 
in PBS was added to each well (Biolegend, San Diego, CA, 
USA) and incubated at room temperature (RT) for 1.5 hours. 
After washing the plate 6 times with PBS, 100 μL of streptavi-
din-alkaline phosphatase (Invitrogen) diluted 1:1000 in PBS 
was added. The plate was incubated at RT for 1 hour in the 
dark and developed with color solution by mixing 10 mL of 
Tris-MgCl2 buffer with 100 μL of NBT solution (Bio-Rad, 
Berkeley, CA, USA) and 100 μL of BCIP solution (Bio-Rad). The 
plate was washed 6 times with water and dried before reading. 
The spots were quantified with an ELISpot plate reader and 
software version 3.5 (AID ELISpot Reader System, Strassberg, 
Germany). Data were obtained by calculating the means of 
triplicate wells. ELISpot data were represented as the total 
IFN-γ spot-forming units (SFU)/3×105 CD8+ T cells. PBMCs 
stimulated with autologous DCs loaded with CMV pp65495-503 
(NLVPMVATV, HLA-A*02;01) or CMV pp6591-100 (SVNVHNPT-
GR, HLA-A*33;03) were used for the positive or negative con-
trol according to the HLA type of donors.
Cell lines and cell culture
The human cervical cancer cell line SNU1299 (HLA-A*02;01/ 
33;03) was purchased from the Korean Cell Line Bank (Seoul, 
South Korea), and was tested and authenticated. The SNU1299 
cell line was expanded and frozen in aliquots within 4 weeks 
of purchase. SNU1299 cells were thawed and cultured at 37°C 
and 5% CO2 in complete RPMI medium for no more than 8 
passages. Immortalized Epstein-Barr virus-B lymphoblastoid 
cell (EBV-BLC) lines (HLA-A*33;03/33;03 or HLA-A*02;01/ 
02;01) and CMV infected-fibroblast (HLA-A*33;03/33;03) were 
cultured at 37°C and 5% CO2 in complete RPMI medium. Cells 
were routinely tested for the absence of mycoplasma.
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Cytotoxicity assay
A cytotoxicity assay was performed employing the 51Cr release 
assay as previously described.11 Briefly, SNU1299 cells were 
labeled for 45 min with 51Cr (100 mCi/106 cells, Perkin Elmer, 
Waltham, MA, USA), and then washed in PBS, and dispensed 
into U-bottom 96-well plates in triplicate (Nunc) at 4×103 cells/
well. Peptide-pulsed PBMCs were added at an effector:target 
ratio of either 10:1, 30:1, 50:1, or 100:1 and CD8+ T cells were 
added at an effector:target ratio of either 1:1, 3:1, 5:1, or 10:1. 
The cells were incubated for 6 hours, and the supernatant was 
analyzed using a WIZARD2 Automatic Gamma Counter (Per-
kin Elmer, Waltham, MA, USA). The spontaneous and total re-
lease for each target were used to calculate the percentage of 
specific release according to the following formula: % specific 
release=(experimental counts per minute-spontaneous counts 
per minute)/(total counts per minute-spontaneous counts per 
minute)×100. For the effectors, PBMCs sensitized with autolo-
gous DCs loaded with CMV pp65495-503 (NLVPMVATV, HLA-
A*02;01) or CMV pp6591-100 (SVNVHNPTGR, HLA-A*33;03) were 
used for the positive or negative control according to the HLA 
type of donors. CMV specific peptide loaded-EBV-BLC or CMV 
infected-fibroblast were used as target cells.
Statistical analysis
Data presented as means±standard errors (SEs) were represen-
tative of at least three independent experiments. The Mann-
Whitney U test was used for non-parametric comparisons of 
two variables. For all statistical analyses, the social sciences 
software package SPSS (version 13.0; SPSS Inc., Chicago, IL, 
USA) was used and a p value of less than 0.05 was considered 
statistically significant.
RESULTS
Screening of specific 15-amino acid candidate epitopes 
using in vitro sensitization
We first determined which of the fourteen HPV 16 E7 peptides 
have immunogenic potency for the generation of CTLs. Thus, 
PBMCs from HLA-A*33;03 donors were sensitized with each of 
the candidate 15-amino acid peptides for one week, and IFN-γ 
production of PBMCs was measured. Among the fourteen 
15-amino acid peptides, HPV 16 E749-63 (RAHYNIVTFCCKCDS) 
induced significantly greater IFN-γ production of PBMCs than 
the other peptides as well as the negative control (p=0.037) 
(Fig. 1A and B). Here, PBMCs from HLA-A*33;03 donors stim-
ulated with autologous DCs loaded with CMV pp65495-503 (NLVP-
MVATV, HLA-A*02;01) and with no peptide were used for the 
negative controls, whereas PBMCs from HLA-A*33;03 donors 
stimulated with autologous DCs loaded with CMV pp6591-100 
(SVNVHNPTGR, HLA-A*33;03) and PHA were used for the 
positive controls.
To provide further evidence, ELISpot assays were performed 
and IFN-γ+ spot forming numbers were counted after in vitro 
sensitization of CD8+ CTLs with each peptide. As shown in Fig. 
1C, E749-63 produced significantly higher numbers of IFN-γ+ 
spots than other candidate peptides and negative control (p= 
0.002). These results imply that E749-63 peptide is potential HLA-
A*33;03-restricted HPV 16 E7 epitopes: PBMCs from HLA-
A*33;03 donors stimulated with autologous DCs loaded with 
CMV pp65495-503 (NLVPMVATV, HLA-A*02;01) and with no pep-
tide were used for the negative controls, whereas PBMCs from 
HLA-A*33;03 donors stimulated with autologous DCs loaded 
with CMV pp6591-100 (SVNVHNPTGR, HLA-A*33;03) and with 
PHA were used for the positive controls.
To confirm the immunogenicity of selected E749-63 peptide 
by a flow cytometry analysis and ELISpot assay, HLA-A*33;03-
restricted cytotoxicity was measured by 51Cr release. E749-63 pep-
tide-sensitized PBMCs from HLA-A*33;03 donors were used 
for two weeks as the effector cells for the 51Cr release assay 
against HLA-A-matched SNU1299 cells. As shown in Fig. 1D, 
PBMCs sensitized with E749-63 showed significantly higher 51Cr 
release than the cells in the negative control group, suggesting 
that E749-63 is a potential HLA-A*3303-restricted HPV 16 E7 epi-
tope. For the positive control, PBMCs stimulated with autolo-
gous DCs loaded with CMV pp6591-100 (SVNVHNPTGR, HLA-
A*33;03) as effectors and CMV infected-fibroblasts (HLA-
A*33;03) were used as the target cells. For the negative control, 
PBMCs stimulated with autologous DCs loaded with CMV 
pp65495-503 (NLVPMVATV, HLA-A*02;01) as effectors and CMV 
infected-fibroblasts (HLA-A*33;03) were used as the target cells.
Ex vivo sensitization of 9- and 10-amino acid peptides 
spanning E749-63
We synthesized a total of thirteen overlapping 9- or 10-amino 
acid peptides spanning E749-63, and used them to determine pr-
ecise HLA-A*33;03-restricted HPV 16 E7 epitopes. After two 
weeks of in vitro sensitization with each of the thirteen candi-
date peptides, intracellular IFN-γ production in PBMCs from 
HLA-A*33;03 donors was assessed using flow cytometry. Among 
these peptides, E750-59 (AHYNIVTFCC)- and E752-61 (YNIVTFC 
CKC)-sensitized PBMCs showed higher IFN-γ production than 
other peptides and negative controls (p=0.036, 0.047, respective-
ly) (Fig. 2A and B). PBMCs from HLA-A*33;03 donors stimulated 
with autologous DCs loaded with CMV pp65495-503 (NLVPM-
VATV, HLA-A*02;01) and with no peptide were used as negative 
controls, while PBMCs from HLA-A*33;03 donors stimulated 
with autologous DCs loaded with CMV pp6591-100 (SVNVHNPT-
GR, HLA-A*33;03) and with PHA as positive controls.
To verify HLA-A*33;03-restricted cytotoxicity induced by 
E761-69 and E767-76, a 51Cr release assay against SNU1299 cells 
was performed using PBMCs from HLA-A*33;03 donors sen-
sitized with E750-59 and E752-61. The results showed that E750-59- 
and E752-61-sensitized PBMCs demonstrated significantly high-
er cytotoxicity against SNU1299 cells than the negative control 
group (Fig. 2C). For the positive control, PBMCs stimulated with 
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autologous DCs loaded with CMV pp6591-100 (SVNVHNPTGR, 
HLA-A*33;03) were used as effectors and CMV infected-fibro-
blasts (HLA-A*33;03) were used as the target cells. For the neg-
ative control, PBMCs stimulated with autologous DCs loaded 
with CMV pp65495-503 (NLVPMVATV, HLA-A*02;01) were used 
as effectors and CMV infected-fibroblasts (HLA-A*33;03) were 
used as the target cells. PBMCs stimulated with autologous 
DCs loaded with no peptide as effectors and SNU1299 cells as 
target cells were used for another negative control.
To further assess the epitope-specificity of the cytotoxic effect 
by these peptide-sensitized PBMCs, we performed a 51Cr re-
lease assay using EBV-BLCs expressing HLA-A*33;03 as target 
cells. PBMCs from HLA-A*33;03 donors sensitized with E750-59 
and E752-61 showed cytolytic effects against EBV-BLCs loaded 
with the same peptide, but not against EBV-BLCs loaded with 
none of peptides (the negative controls) (Fig. 2D). PBMCs from 
HLA-A*33;03 donors sensitized with CMV pp6591-100 (SVNVH-
NPTGR, HLA-A*33;03) and EBV-BLCs loaded with the same 
peptide were used as the positive control.
In addition, higher CD69 expression on CD8+INF-γ+ CTLs 
was consistently induced by sensitization of E750-59 and E752-61 
peptides than for the negative control group (Fig. 2E).
Fig. 1. Quantitation of IFN-γ production and a cytotoxicity assay of candidate 15-amino acid peptide-sensitized CTLs. (A) Flow cytometry analyses 
were performed to measure intracellular IFN-γ production of PBMCs sensitized with candidate peptides. E749-63 induced significantly higher IFN-γ 
production in PBMCs from HLA-A*33;03 subjects than negative controls (non-peptide). The data are representative of ten independent experiments 
using PBMCs from HLA-A*33;03 subjects. (B) The bar graph depicts the numbers of each peptide-specific INF-γ+CD8+ T cells per 7.5×104 PBMCs. 
Columns, mean (n=10); bars, SE. (C) ELISpot assays were performed to measure IFN-γ production from CD8+ CTL that were sensitized with fourteen 
candidate peptides. HPV 16 E749-63 induced greater number of IFN-γ+ spots from CD8+ CTLs of HLA-A*33;03 donors than other peptides as well as 
negative control. The bar graph depicts the numbers of SFU of INF-γ produced by CD8+ T cells. Columns, mean (n=6); bars, SE. (D) E749-63 (△)-sensi-
tized PBMCs lysed a significantly higher number of SNU1299 cells than negative control in a cytotoxic assay using 51Cr release. Point, mean (n=10); 
bars, SE. CMV A33 (○)-sensitized PBMCs was used as a positive control and non-peptide (●) or CMV A02 (▼)-sensitized PBMCs were used as 
negative controls matched with each donor’s HLA type. All statistically significant differences between the test group and the control group (non-
peptide) were determined using the Mann-Whitney U test. *p<0.05, **p<0.01. IFN-γ, interferon-γ; CTLs, cytotoxic T lymphocytes; PBMCs, peripheral 
blood mononuclear cells; SE, standard error; HPV, human papillomavirus.
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E750-59- and E752-61-specific cytotoxicity was 
induced by CD8+ CTLs
We further examined whether the cytotoxicity of peptide-sen-
sitized PBMCs was related to cytolytic activity of CD8+ CTLs in 
PBMCs. Thus, 51Cr release assays were performed using isolated 
CD8+ CTLs and CD8+ T lymphocyte-depleted PBMCs against 
SNU1299 cells. E749-63-sensitized CD8+ CTLs showed signifi-
cantly higher cytolytic effects against SNU1299 cells than the 
CD8+ T lymphocyte-depleted PBMCs as well as the negative 
control group (PBMCS stimulated with no peptide) (Fig. 3A). 
Additionally, when we performed a cytotoxicity assay using 
E750-59 and E752-61-sensitized CD8+ CTLs, the cytotoxicity against 
SNU1299 cells was higher than that of CD8+ T lymphocyte-de-
pleted PBMCs as well as the negative control group (PBMCS 
stimulated with no peptide) (Fig. 3B).
DISCUSSION
Currently, approximately 500000 newly diagnosed cases of 
cervical cancer with an approximately 50% mortality rate are 
reported each year worldwide.17 Since conventional treatments 
against early-stage, late-stage, or recurrent cervical cancer are 
associated with a high probability of recurrence,18,19 there is still 
a need to develop innovative immune therapeutic methods that 
can be combined with current treatment to further improve the 
Fig. 2. Quantitation of intracellular IFN-γ production and a cytotoxicity assay of candidate 9- or 10-amino acid peptide-sensitized CTLs. (A) E750-59 and 
E752-61 induced significantly higher IFN-γ production in PBMCs from HLA-A*33;03 subjects than negative controls (non-peptide). The data are repre-
sentative of ten independent experiments using PBMCs from HLA-A*33;03 subjects. (B) The bar graph depicts the number of each peptide-specific 
INF-γ+CD8+ T cells per 7.5×104 PBMCs. Columns, mean (n=10); bars, SE. Statistically significant differences between the test group and the non-pep-
tide group were determined using the Mann-Whitney U test. *p<0.05, **p<0.01. (C) E750-59 (△)- and E752-61 (■)-sensitized PBMC lysed a significantly 
higher number of SNU129 cells than negative control (non-peptide, ●). CMV A33 (○)-sensitized PBMCs was used as a positive control and CMV A02 
(▼)-sensitized PBMCs was used as a negative control. Point, mean (n=10); bars, SE. (D) E750-59 (▼)- and E752-61 (△)-sensitized PBMCs lysed a signifi-
cantly higher number of EBV-BLCs than negative control. CMV A33 (○)-sensitized PBMCs was used as a positive control and non-peptide sensitized-
PBMCs (none, ●) or non-peptide pulsed-EBV-BLCs (■, □) were used as negative controls. Point, mean (n=10); bars, SE. (E) CD69 expression by 
CD8+ T cells was measured by flow cytometry to determine the activation of CD8+ CTLs after a 1-week sensitization with each candidate peptide, 
and E750-59 and E752-61 -sensitized CD8+ CTLs expressed higher quantities of CD69 than negative control. CMV A33-sensitized CD8+ CTLs were used as 
a positive control and non-peptide or CMV A02-sensitized CD8+ CTLs were used as negative controls. Data are representative of four independent 
experiments using PBMCs from HLA-A*3303 subjects. IFN-γ, interferon-γ; CTLs, cytotoxic T lymphocytes; PBMCs, peripheral blood mononuclear 
cells; SE, standard error; EBV-BLCs, Epstein-Barr virus-B lymphoblastoid cells.
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survival rate of patients with cervical cancer.
Previous studies have shown that HPV 16-specific CD8+ T cell 
responses play a critical role in the regression of HPV 16-infect-
ed precancerous lesions and also in the clearance of HPV 16-in-
duced cervical cancer.20,21 Because the HPV E6 and E7 proteins 
are constitutively expressed in both HPV-infected cells and cer-
vical cancer cells, these oncoproteins are potential targets for 
immunotherapy against HPV-associated disease. Therefore, the 
identification of immunodominant epitopes from HPV E6 and 
E7 for cytotoxic CD8+ T cells is indispensable for CTL-based 
immunotherapy in cervical cancer. Although HLA-A33 is a com-
mon HLA-A molecule expressed in humans, HLA-A33-restrict-
ed HPV 16 E7 epitopes have not yet been identified. Here, we 
identified new HLA-A*33;03-restricted HPV 16 E7 specific epi-
topes using 15-amino acid peptides overlapped by 8 residues 
covering the full-length HPV 16 E7 protein. 
In the present study, 15-amino acid peptides were synthe-
sized and flow cytometry and ELISpot assay were used to mea-
sure INF-γ production in PBMCs from HLA-A*33;03 donors. 
Among the fourteen 15-amino acids peptides, HPV E749-63 in-
duced significantly higher IFN-γ production in PBMCs than 
other peptides, and the 51Cr releasing assay showed that these 
peptides induced a cytotoxic effect against SNU1299 cells (Fig. 
1). The virally-infected cancer cells can be recognized by CD8+ 
T cells through immunogenic protein fragments of 8 to 12 ami-
no acids generated by extracellular antigen processing on the 
cell surface with HLA class I molecules.22 Therefore, we synthe-
sized six 9-amino acid peptides with 8 overlapping residues 
and seven 10-amino acid peptides with 9 overlapping residues 
spanning E746-93, and established precise HLA-A*33;03-restrict-
ed HPV 16 E7 epitopes. Consequentially, two of the thirteen pe-
ptides induced significantly higher IFN-γ production in PBMCs 
(Fig. 2A). Additionally, we found that the two selected E7 pep-
tides were present in the HLA-A*33;03 molecules of SNU1299 
cells and they strongly induced cytotoxicity against SNU1299 
cells (Fig. 2C) similar to selected E7 peptide-pulsed EBV-BLCs 
(Fig. 2D). These results indicate that they are naturally processed 
and present in human cervical cancer cells, and that peptide-
sensitized CTL recognized and lysed E750-59- and E752-61-loaded 
cervical cancer cells. Furthermore, we investigated whether pe-
ptide-specific cytotoxicity was induced by the cytotoxic effect 
of CD8+ CTLs included in PBMCs, and found that the E750-59- 
and E752-61-sensitized and isolated CD8+ CTLs from PBMCs 
demonstrated significantly greater cytotoxicity than CD8-de-
pleted PBMCs against SUN1299 cells (Fig. 3), thus confirming 
that the cytolytic effect of CD8+ CTLs is critical for peptide-
based immunotherapy in cervical cancer. 
Some limitation might be found in this study. A previous st-
udy reported that the specificity of tumor cell lysis by peptide-
induced CTL should be interpreted with caution, because CTL 
reactivity against cervical cancer cell lines could possibly be 
due to cross-reactivity on allogeneic HLA molecules rather than 
to E7 recognition.23 Others reported also that this type of vac-
cine therapy may ultimately be better suited for the treatment 
of patients with pre-invasive disease, because less advanced le-
sions such as high-grade dysplasia or carcinoma in situ are gen-
erally much smaller lesions that are more stable genetically.24 
However, more recent studies showed many therapeutic HPV 
vaccines in clinical trials with promising results. In these stud-
ies, adoptive T-cell therapy showed clinical activity in a phase 
II trial involving advanced cervical cancer patients. Several tri-
als, involving peptide-protein-based vaccines and live-vector 
based vaccines, also demonstrated that these approaches are 
effective in cervical intraepithelial neoplasia (CIN) as well as in 
Fig. 3. HPV 16 E7 peptide-specific cytotoxicity by the cytolytic effect of CD8+ CTLs in PBMCs (A) E749-63-sensitized- and isolated-CD8+ CTLs (■) as well 
as E749-63-sensitized PBMCs (○) lysed significantly greater quantities of SNU1299 cells than the CD8+ T lymphocyte-depleted PBMCs (△) and non-
peptide sensitized-PBMCs (●) used as a negative control. Point, mean (n=7); bar, SE. (B) E750-59 (▼)- and E752-61 (△)-sensitized and isolated-CD8+ CTLs 
also showed significantly higher cytotoxicity against SNU1299 cells than CD8+ T lymphocyte-depleted PBMCs (■, □) as well as the negative control 
(non-peptide, ●). Point, mean (n=7); bar, SE.  HPV, human papillomavirus; PBMCs, peripheral blood mononuclear cells; SE, standard error; CTLs, cyto-
toxic T lymphocytes.
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advanced cervical cancer (CC) patients. HPV therapeutic vac-
cines must be regarded as a therapeutic option in cervical dis-
ease.25 The strength of the present study is the fact that identi-
fied HPV 16 E7 specific peptides could play an important role 
as a basic platform for both the development of peptide-in-
duced CTL vaccines and development of peptide-based CTL 
immune monitoring system which are very specific for HLA-
A33 cervical cancer patients in Korean and Asian peoples. Fur-
thermore, identified HPV 16 E7 specific peptides in this study 
could be used for combination of HPV therapeutic vaccines 
with radiotherapy, chemotherapy, immunomodulators or im-
mune checkpoint inhibitors, and would open a new and inter-
esting scenario for HPV 16 E7 positive cancers including cer-
vix cancer and oropharyngeal cancer in near future. 
In summary, we identified novel HPV 16 E7 epitopes E761-69 
and E767-76 for the HLA-A*33;03 allele and showed that E761-69- 
and E767-76-sensitized PBMC as well as CD8+ CTLs have an anti-
tumor cytotoxic effect against cervical cancer cells. These epit-
opes might be helpful for immunotherapy and immune 
monitoring for cervical cancer as well as other HPV 16-assocat-
ed diseases.
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